Myomo (MYO)
(Delayed Data from AMEX)
$3.93 USD
+0.13 (3.42%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.92 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.93 USD
+0.13 (3.42%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.92 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
by Zacks Equity Research
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
by Zacks Equity Research
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
by Zacks Equity Research
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
Will Myomo, Inc. (MYO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -5.00% and -25.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -10.53% and 1.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?